文献速递其他结缔组织病

美洲原住民中的他汀相关免疫介导坏死性肌病

Statin-associated immune-mediated necrotizing myositis in Native Americans.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究比较美洲原住民中他汀相关免疫介导坏死性肌病(IMNM)与特发性炎症性肌病(IIM)的表现,纳入21例炎症性肌病患者。IMNM占52.4%,患者年龄更大,糖尿病、高脂血症、他汀暴露、CK升高、抗HMGCR抗体及坏死性肌病比例更高,而病程更短、雷诺现象、皮肤表现及自身抗体更少;IVIG使用更多。

要点

  • 美洲原住民炎症性肌病中IMNM占52.4%,均伴他汀暴露、糖尿病和高脂血症。
  • IMNM表现为CK显著升高、坏死性肌病和抗HMGCR抗体,皮肤及血管表现少。
  • IMNM较IIM更多使用IVIG(72.7% vs 11.1%,P=0.009)。

核心结论

  • IMNM可发生于美洲原住民,与糖尿病、高脂血症、他汀使用及年龄较大相关,以CK显著升高、坏死性肌病和抗HMGCR抗体为特征,皮肤或血管表现少。

研究设计与样本

  • 研究纳入21例美洲原住民炎症性肌病患者,记录糖尿病、高脂血症、他汀暴露、肌病诊断、肌肉组织学、自身抗体及肌炎特异性抗体、治疗和转归。

主要发现

  • IMNM占52.4%,IIM占42.9%,代谢性肌病占4.8%。
  • IMNM组 vs IIM组年龄61.6岁(s.d. 9.8) vs 39.8岁(14.3),糖尿病100% vs 55.6%,高脂血症100% vs 33.3%,他汀暴露100% vs 22.2%。
  • IMNM组 vs IIM组CK 11 780 IU(s.d. 7064) vs 1707 IU(1658),抗HMGCR抗体85.7% vs 11.1%,坏死性肌病81.8% vs 11.1%。
  • IMNM组 vs IIM组病程26.2个月(s.d. 395) vs 78.4个月(47.9),雷诺现象9.1% vs 55.6%,皮肤表现0% vs 55.6%,ANA 18.2% vs 66.7%,任何自身抗体18.2% vs 88.9%(均P<0.05)。
  • MRI异常、组织学肌炎、肌炎特异性抗体、肺动脉高压、食管功能障碍、间质性肺病、残疾及持续CK升高两组相似。

关键数值与推荐

  • IMNM组 vs IIM组IVIG治疗72.7% vs 11.1%(P=0.009),抗代谢药45.5% vs 88.9%(P=0.05),利妥昔单抗18.2% vs 55.6%(P=0.09)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Statin-associated immune-mediated necrotizing myopathy (IMNM) and idiopathic inflammatory myositis (IIM) are myopathies with overlapping features. This study compared the manifestations of IMNM to IIM in Native Americans. METHOD: Twenty-one Native American patients with inflammatory myopathy (IM) were characterized as to diabetes mellitus, hyperlipidaemia, statin exposure, myopathy diagnosis, muscle histology, autoimmune and myositis-specific autoantibodies, therapy and outcome. RESULTS: IM consisted of 52.4% IMNM, 42.9% IIM and 4.8% metabolic myopathy. IMNM vs IIM patients were older [61.6 years (s.d. 9.8) vs 39.8 (14.3)], diabetes mellitus (100% vs 55.6%), hyperlipidaemia (100% vs 33.3%), statin-exposure (100% vs 22.2%), creatine kinase [CK; 11 780 IU (s.d. 7064) vs 1707 (1658)], anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibodies (85.7% vs 11.1%) and necrotizing IM (81.8% vs 11.1%), but shorter disease duration [26.2 months (s.d. 395) vs 78.4 (47.9)], RP (9.1% vs 55.6%), cutaneous manifestations (0% vs 55.6%), ANA (18.2% vs 66.7%) or any autoantibody (18.2% vs 88.9%) (all P < 0.05). MRI abnormalities, histologic IM, myositis-specific autoantibodies, pulmonary hypertension, oesophageal dysfunction, interstitial lung disease, disability and persistently elevated CK were similar. IMNM vs IIM was treated more with IVIG (72.7% vs 11.1%; P = 0.009) and less with antimetabolites (45.5% vs 88.9%; P = 0.05) and rituximab (18.2% vs 55.6%; P = 0.09). CONCLUSIONS: IMNM may occur in Native Americans and is associated with diabetes mellitus, hyperlipidaemia, statin use and older age and is characterized by marked CK elevation, necrotizing myopathy and anti-HMGCR antibodies with few cutaneous or vascular manifestations.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Muruganandam M, Iqbal A, Akpan EB, et al. Statin-associated immune-mediated necrotizing myositis in Native Americans. Rheumatology (Oxford). 2022. PMID: 35348616. doi:10.1093/rheumatology/keac198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。